Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 997 Cr.
- Current Price ₹ 361
- High / Low ₹ 513 / 263
- Stock P/E 34.8
- Book Value ₹ 101
- Dividend Yield 0.28 %
- ROCE 8.22 %
- ROE 8.87 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 3.58 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.04% over past five years.
- Tax rate seems low
- Company might be capitalizing the interest cost
- Dividend payout has been low at 2.97% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
171 | 205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 673 | 473 | |
158 | 186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 566 | 397 | |
Operating Profit | 13 | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 107 | 76 |
OPM % | 7% | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 16% | 16% |
0 | 0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | 2 | -105 | |
Interest | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 23 | 30 |
Depreciation | 8 | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 27 | 28 |
Profit before tax | -2 | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 |
Tax % | -31% | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 26% | -3% |
-1 | 2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | |
EPS in Rs | -1.18 | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 5% |
3 Years: | -10% |
TTM: | -30% |
Compounded Profit Growth | |
---|---|
10 Years: | 31% |
5 Years: | 12% |
3 Years: | -30% |
TTM: | -33% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | -8% |
1 Year: | -2% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 19% |
3 Years: | 15% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 |
Reserves | 26 | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 |
72 | 72 | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | |
31 | 43 | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 119 | 154 | |
Total Liabilities | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 901 | 765 |
54 | 56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 255 | |
CWIP | 5 | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
72 | 87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 514 | 506 | |
Total Assets | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 901 | 765 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14 | 17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | |
-8 | -9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | |
-7 | -8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 132 | -97 | |
Net Cash Flow | -0 | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 123 | 139 |
Inventory Days | 43 | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 191 | 206 |
Days Payable | 51 | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 78 | 128 |
Cash Conversion Cycle | 87 | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 237 | 217 |
Working Capital Days | 71 | 62 | 52 | 52 | 58 | 61 | 66 | 76 | 90 | 142 | 204 | 254 |
ROCE % | 5% | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 12% | 8% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Jul - Newspaper publication informing about completion of EGM notice dispatch to shareholders and e-voting details.
-
Board Meeting Outcome for Revised Outcome
15 Jul - Revised outcome of Board Meeting held on 10th July, 2024
- EGM On 7Th August, 2024 Through VC/OAVM 15 Jul
- Announcement under Regulation 30 (LODR)-Preferential Issue 10 Jul
- Board Meeting Outcome for Outcome Of Board Meeting Held On 10Th July, 2024 10 Jul
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.